Detalhe da pesquisa
1.
A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation.
Mol Cancer
; 23(1): 54, 2024 03 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38486218